Valeant Pharmaceuticals Intl Inc (VRX) Lifted to “Buy” at TD Securities
Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) was upgraded by research analysts at TD Securities from a “hold” rating to a “buy” rating in a report released on Wednesday. The firm currently has a C$25.50 price objective on the specialty pharmaceutical company’s stock. TD Securities’ price objective would indicate a potential upside of 34.71% from the company’s current price.
Separately, Royal Bank Of Canada lowered their price objective on Valeant Pharmaceuticals Intl to C$22.50 and set a “sector perform” rating for the company in a research note on Friday, October 20th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Valeant Pharmaceuticals Intl presently has an average rating of “Hold” and an average price target of C$22.50.
Shares of Valeant Pharmaceuticals Intl (TSE VRX) traded up C$0.84 during midday trading on Wednesday, reaching C$18.93. The company’s stock had a trading volume of 3,529,047 shares, compared to its average volume of 1,280,000. Valeant Pharmaceuticals Intl has a 12-month low of C$11.20 and a 12-month high of C$26.24.
In other news, Director Schutter Richard Urbain De bought 4,900 shares of the firm’s stock in a transaction dated Monday, August 21st. The stock was bought at an average price of C$14.35 per share, for a total transaction of C$70,315.00.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.